1. Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trial

   • Martin A. Graham
   • Suresh Senan
   • Paul Workman

   ORIGINAL ARTICLE Pages: 1 - 10

2. Quantitative relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity in rats: importance of area under the concentration-time curve (AUC) as the major toxicodynamic determinant in vivo

   • Naomi Nagai
   • H. Ogata

   ORIGINAL ARTICLE Pages: 11 - 18

3. Arterial occlusion in patients with peripheral vascular disease treated with platinum-based regimens for lung cancer

   • John Mathews
   • Rakesh Goel
   • D. J. Stewart

   ORIGINAL ARTICLE Pages: 19 - 22

4. Cellular uptake and antitumor activity of the new anthracycline analog DA-125 in human cancer cell lines

   • Kyoung-Hwa Lim
   • Hun-Sik Kim
   • J.-G. Park

   ORIGINAL ARTICLE Pages: 23 - 30

5. Overexpression of thioredoxin does not confer resistance to cisplatin in transfected human ovarian and colon cancer cell lines

   • Manabu Yamada
   • Akihiro Tomida
   • T. Tsuruo

   ORIGINAL ARTICLE Pages: 31 - 37

6. Effect of glutathione depletion on the cytotoxicity of cisplatin and iproplatin in a human melanoma cell line

   • L. Pendyala
   • R. Perez
   • P. J. Creaven

   ORIGINAL ARTICLE Pages: 38 - 44

7. Pharmacokinetics of trofosfamide and its dechloroethylated metabolites

   • G. Hempel
   • Sebastian Krümpelmann
   • Joachim Boos

   ORIGINAL ARTICLE Pages: 45 - 50

8. Combination chemotherapy involving orally administered etoposide and JM-216 in murine tumor models

   • William C. Rose

   ORIGINAL ARTICLE Pages: 51 - 56

9. Quantification of 4-hydroxyifosfamide in plasma of ifosfamide-treated mice

   • R. F. Struck
   • D. M. McCain
   • K. H. Tillery

   ORIGINAL ARTICLE Pages: 57 - 59

10. Depletion of p185erbB2, Raf-1 and mutant p53 proteins by geldanamycin derivatives correlates with antiproliferative activity

    • Won G. An
    • Rodney C. Schnur
    • M. V. Blagosklonny

    ORIGINAL ARTICLE Pages: 60 - 64

11. Characterization of cellular accumulation and toxicity of illudin S in sensitive and nonsensitive tumor cells

    • M. J. Kelner
    • Trevor C. McMorris
    • Raymond Taetle

    ORIGINAL ARTICLE Pages: 65 - 71

12. Thiotepa and etoposide treatment of recurrent malignant gliomas: phase I study

    • Casilda Balmaceda
    • M. R. Fetell
    • Charles Hesdorffer

    ORIGINAL ARTICLE Pages: 72 - 74

13. Glutathione content but not gamma glutamyl cysteine synthetase mRNA expression predicts cisplatin resistance in head and neck cancer cell lines

    • Kenneth Newkirk
    • Joseph Heffern
    • Kevin J. Cullen

    ORIGINAL ARTICLE Pages: 75 - 80

14. An investigation of the antitumour activity and biodistribution of polymeric micellar paclitaxel

    • Xichen Zhang
    • Helen M. Burt
    • W. L. Hunter

    ORIGINAL ARTICLE Pages: 81 - 86

15. Host distribution and response to antitumor alkylating agents of EMT-6 tumor cells from subcutaneous tumor implants

    • Sylvia A. Holden
    • Yasunori Emi
    • B. A. Teicher

    ORIGINAL ARTICLE Pages: 87 - 93

16. Establishment of a cisplatin-resistant gastric carcinoma cell line OCUM-2M/DDP

    • Atsunori Nitta
    • Yong-Suk Chung
    • Michio Sowa

    SHORT COMMUNICATION Pages: 94 - 97